Manegement of progressive supranuclear palsy with recurrent falls, depressive symptoms and presential hallucinations
Reading File
Finding Sources
Searching PubMed
"progressive supranuclear palsy" AND management
Searching the Web
progressive supranuclear palsy management recurrent falls depression hallucinations 2024 2025
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
I now have comprehensive content from multiple authoritative textbooks. I have enough to write a thorough clinical response. Let me compose the answer now.
Management of Progressive Supranuclear Palsy (PSP): Recurrent Falls, Depressive Symptoms, and Presential Hallucinations
PSP is a 4-repeat tauopathy (FTLD-tau class) with no disease-modifying therapy currently available. Management is entirely symptomatic and multidisciplinary. The three problems you mention - recurrent falls, depression, and presential (presence) hallucinations - each require a specific approach layered over the general supportive framework.
Overview: General Principles
- No pharmacological agent has demonstrated disease-modifying benefit in PSP.
- Levodopa is ineffective in most patients (postsynaptic D2 receptor depletion in the striatum), though a temporary, partial response to levodopa in ~40% of patients may be seen early - primarily for bradykinesia, not gait or balance.
- Cholinergic agents (donepezil) showed modest cognitive benefit in one RCT but poor tolerability; routine use is not supported.
- Tideglusib (GSK-3 inhibitor) and davunetide (microtubule stabilizer) were safe but failed to show clinical efficacy in PSP rating scale outcomes.
- Care is largely supportive, rehabilitative, and palliative.
Bradley and Daroff's Neurology in Clinical Practice, p. 2108; Kaplan & Sadock's Comprehensive Textbook of Psychiatry, p. 1738
1. Recurrent Falls
Falls in PSP arise from a combination of axial rigidity, impaired downgaze (inability to see the ground), frontal executive dysfunction impairing hazard judgment, and a characteristic "toppling" gait with retroflexion posture.
Non-Pharmacological (First-Line)
| Intervention | Rationale |
|---|---|
| Weighted walking aids (e.g., wheeled walker with anterior weight) | Counteracts backward toppling tendency - PSP falls are characteristically backward |
| Physiotherapy | Preserves joint mobility, gait training, fall prevention exercises; no proven benefit in RCTs but maintains function |
| Occupational therapy | Home safety assessment, removal of trip hazards, grab-rails, adaptive equipment |
| Prism glasses / bifocals | Compensates for impaired downgaze; helps with navigating stairs |
| Speech therapy | Manages dysphagia (aspiration is a leading cause of death); PEG tube when needed |
| Hip protectors | Reduces injury from falls |
Pharmacological
- Levodopa/carbidopa: Trial warranted - ~40% show some short-term improvement in bradykinesia/rigidity; does not improve gait or balance meaningfully. A marked response should prompt reconsideration of the diagnosis (toward PD).
- Botulinum toxin: Useful for retrocolic (neck hyperextension) dystonia and blepharospasm, both of which contribute to gait instability and falls.
- Zolpidem (gabanergic GABA-A agonist): Some reports of transient benefit for akinesia and rigidity in PSP, but evidence is anecdotal - requires caution given fall risk from sedation.
- Benztropine / trihexyphenidyl (anticholinergic): May reduce dystonia modestly, though botulinum toxin is preferred for focal signs.
- Avoid benzodiazepines and any agent that worsens sedation or orthostasis.
Adams and Victor's Principles of Neurology, p. 1100-1101; Bradley and Daroff's Neurology, p. 2108; AFTD.org
2. Depressive Symptoms
Depression is highly prevalent in PSP - affecting approximately 44-60% of patients - more common than in age-matched general populations. It frequently co-occurs with apathy (which can be mistaken for depression). Distinguishing the two matters for treatment choice:
- Apathy (most common psychiatric feature): reduced initiative, loss of motivation, blunted affect - reflects frontal-subcortical circuit disruption
- Depression: dysphoric mood, hopelessness, tearfulness, vegetative features - distinct from apathy though they overlap
Pharmacological Options
| Drug Class | Notes |
|---|---|
| SSRIs (e.g., sertraline, citalopram, fluoxetine) | First-line for depression in PSP; generally well-tolerated |
| Tricyclic antidepressants (amitriptyline, imipramine) | Useful for depression and pseudobulbar affect (emotional lability, pathological crying/laughing); benefit appears independent of antidepressant effect |
| Amitriptyline | Specifically noted in multiple sources as helpful for pseudobulbar affect / emotional incontinence in PSP |
| Dextromethorphan/quinidine (Nuedexta) | FDA-approved for pseudobulbar affect; used when emotional lability is prominent |
| Methylphenidate / modafinil | Sometimes used off-label for prominent apathy, though evidence is limited |
Note: Amitriptyline's anticholinergic side effects (falls, confusion, dry mouth, urinary retention) require caution in elderly PSP patients already prone to falls. Start at low doses.
Non-Pharmacological
- Caregiver education and support - caregiver burden is high in PSP
- Neuropsychiatric support, counseling for patient and family
- Palliative care referral as disease advances
Bradley and Daroff's Neurology, p. 2108; Kaplan & Sadock's Psychiatry, p. 1738; BCM Medicine; AFTD.org
3. Presential Hallucinations
"Presential hallucinations" (sense of presence hallucinations - feeling someone is in the room when no one is) are a recognized phenomenon in neurodegenerative parkinsonian diseases. They sit on a spectrum with frank visual hallucinations.
Key Diagnostic Consideration
Prominent visual hallucinations in PSP should prompt differential review. Visual hallucinations are:
- Not a characteristic feature of classic PSP-Richardson syndrome - their presence should raise suspicion for Dementia with Lewy Bodies (DLB) or Parkinson's Disease with Dementia (PDD), where they are a core feature
- In the differential of PSP, DLB must be excluded - DLB features fluctuating cognition, well-formed visual hallucinations, and REM sleep behavior disorder
- Occasionally, PSP can manifest schizophreniform psychotic symptoms in atypical presentations
If the diagnosis of PSP-Richardson is well-established and hallucinations are present, consider:
- Medication review - levodopa and dopamine agonists can cause or worsen hallucinations
- Metabolic/medical causes (delirium, infection, electrolyte disturbance)
Management of Hallucinations in PSP
| Approach | Details |
|---|---|
| Reduce/eliminate dopaminergic drugs | Levodopa/dopamine agonists are the most common iatrogenic cause of hallucinations in parkinsonian disease; reduce or stop if tolerated |
| Quetiapine | Low-dose atypical antipsychotic; most commonly used in parkinsonian hallucinations due to lowest D2 blockade; start 12.5-25 mg at night |
| Clozapine | Most evidence-based for parkinsonian psychosis; requires regular blood monitoring (agranulocytosis risk); reserved for refractory cases |
| Avoid conventional antipsychotics (haloperidol, chlorpromazine) and high-potency atypicals (risperidone, olanzapine) | Severe neuroleptic sensitivity in Lewy body spectrum; and significant worsening of parkinsonism in PSP |
| Rivastigmine | If there is cognitive impairment and hallucinations resembling DLB spectrum |
If the full clinical picture shifts toward DLB (fluctuating cognition, REM sleep behavior disorder, marked neuroleptic sensitivity), reconsider and update the working diagnosis, as it substantially changes management.
Kaplan & Sadock's Psychiatry, pp. 1737-1738; Bradley and Daroff's Neurology; Washington Manual of Medical Therapeutics
4. Multidisciplinary and Supportive Framework
| Domain | Action |
|---|---|
| Swallowing / nutrition | Speech therapy assessment early; modified diet textures; PEG tube if aspiration risk is high |
| Communication | AAC (augmentative and alternative communication) devices as dysarthria progresses |
| Sleep | REM sleep behavior disorder managed with clonazepam; address insomnia |
| Urinary | Bladder dysfunction (frequency, urgency) common; anticholinergics if needed (watch cognitive effects) |
| Advance care planning | Early discussion given ~5-10 year prognosis and trajectory |
| Palliative care | Integrate early; most patients die from aspiration pneumonia complications |
| Caregiver support | High caregiver burden; refer to PSP Society resources |
Summary Table
| Problem | First-Line | Second-Line / Adjunct |
|---|---|---|
| Recurrent falls | Physiotherapy, weighted walker, home OT, prism glasses | Levodopa trial, botulinum toxin (retrocolis/blepharospasm) |
| Depression | SSRIs | Amitriptyline (also treats pseudobulbar affect), Nuedexta for pseudobulbar affect |
| Presential / visual hallucinations | Stop/reduce dopaminergic agents | Low-dose quetiapine; clozapine if refractory |
Recent Evidence Note (PubMed 2023-2026)
A 2026 global review on PSP (PMID 40898879) and a 2025 Continuum review (PMID 40748119) confirm there is still no approved disease-modifying therapy. Clinical trials targeting tau aggregation (anti-tau antibodies, tau vaccines) are ongoing but have not yet yielded approved treatments. The 2024 diagnosis and treatment review by Currens & Pantelyat (Curr Treat Options Neurol) further clarifies the eight MDS-defined PSP clinical variants and endorses the symptomatic approach described above.
Sources: Bradley and Daroff's Neurology in Clinical Practice (p. 2107-2108) | Adams and Victor's Principles of Neurology 12e (p. 1100-1101) | Kaplan & Sadock's Comprehensive Textbook of Psychiatry (pp. 1737-1739) | Harrison's Principles of Internal Medicine 22E | BCM Medicine | AFTD | PubMed PMIDs: 40898879, 40748119, 37381926
This is a shared conversation. Sign in to Orris to start your own chat.